Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Millward

Showing results (191-200 of 224) with videos related to

Pageof 23
Sort By:
British Journal of Cancer|September 14, 2006
The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic studyM J Millward, C House, D Bowtell, et al.
Physical Chemistry Chemical Physics : PCCP|June 26, 2026
Stark absorption spectroscopy of flavin mononucleotide and derivatives of pyrene, xanthene, phenoxazine, and thienotetraceneKatelyn M Duncan, Cornelius J van Galen, Karl J Thorley, et al.
Cancer|April 2, 2011
A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanomaJohn M Kirkwood, Rene Gonzalez, Douglas Reintgen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 17, 2012
A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesotheliomaAnna K Nowak, Michael J Millward, Jenette Creaney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Phase I trial of cremophor EL with bolus doxorubicinM J Millward, L K Webster, D Rischin, et al.
Seminars in Oncology|August 24, 1999
Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancerT Le Chevalier, J Bérille, J R Zalcberg, et al.
Frontiers in Oncology|April 11, 2022
Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint TherapyCaitlin M Tilsed, Thomas H Casey, Emma de Jong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 21, 2007
Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scansRoslyn J Francis, Michael J Byrne, Agatha A van der Schaaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparisonG C Toner, J D Shapiro, C R Laidlaw, et al.
Targeted Oncology|December 1, 2017
Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLCMark J McKeage, Dusan Kotasek, Ben Markman, et al.
Pageof 23

Showing results (191-200 of 224) with videos related to

Sort By:
Pageof 23
British Journal of Cancer|September 14, 2006
The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic studyM J Millward, C House, D Bowtell, et al.
Physical Chemistry Chemical Physics : PCCP|June 26, 2026
Stark absorption spectroscopy of flavin mononucleotide and derivatives of pyrene, xanthene, phenoxazine, and thienotetraceneKatelyn M Duncan, Cornelius J van Galen, Karl J Thorley, et al.
Cancer|April 2, 2011
A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanomaJohn M Kirkwood, Rene Gonzalez, Douglas Reintgen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 17, 2012
A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesotheliomaAnna K Nowak, Michael J Millward, Jenette Creaney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Phase I trial of cremophor EL with bolus doxorubicinM J Millward, L K Webster, D Rischin, et al.
Seminars in Oncology|August 24, 1999
Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancerT Le Chevalier, J Bérille, J R Zalcberg, et al.
Frontiers in Oncology|April 11, 2022
Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint TherapyCaitlin M Tilsed, Thomas H Casey, Emma de Jong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 21, 2007
Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scansRoslyn J Francis, Michael J Byrne, Agatha A van der Schaaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparisonG C Toner, J D Shapiro, C R Laidlaw, et al.
Targeted Oncology|December 1, 2017
Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLCMark J McKeage, Dusan Kotasek, Ben Markman, et al.
Pageof 23